Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2022-04-25
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of selinexor and carfilzomib when
given together with dexamethasone in treating patients with multiple myeloma that has
returned or does not respond to treatment. Drugs used in chemotherapy, such as selinexor and
dexamethasone, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Carfilzomib
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Giving selinexor, carfilzomib, and dexamethasone may be a better treatment for multiple
myeloma.